Good morning and welcome to Markets Desk, your midday read on what's moving markets and why.
Semiconductors now command an unprecedented share of the S&P five hundred, and history suggests that concentration carries real risk. When a single sector drives index returns this decisively, any rotation out of AI-linked names can translate quickly into broad market pain — and right now, that exposure is as high as it has ever been.
Turning to energy, Brent crude is sitting at one hundred ten dollars and eighty-seven cents a barrel this morning, up roughly sixty-five percent from a year ago. That kind of sustained move reshapes everything from airline margins to consumer discretionary spending, and it keeps the Federal Reserve's inflation calculus considerably more complicated heading into the back half of the year.
And on the pharma side, Eli Lilly released positive phase three data for both Zepbound and Foundaya in weight-loss maintenance trials. The SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies showed patients holding their results on lower doses — a meaningful finding that strengthens the durability argument for this drug class and keeps Lilly's competitive moat looking very wide indeed.
That's the tape. Markets Desk, signing off the floor.
